ClinicalTrials.gg
CompletedNCT06610890Updated Dec 3, 2025

Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets

A Phase 1 interventional study of Hemay005 and Midazolam maleate in Psoriasis, sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Hemay005 in Psoriasis — 1 open to participants now, 1 under way, none of them phase 3. Hemay005 · Psoriasis.

Enrollment
8th of 10
20 · median 25
Started
2024
with 3 others
Phase 1
8 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
4 of 10
Ganzhou Hemay Pharmaceutical Co., Ltd

Among the 10 studies testing Hemay005 in Psoriasis, this one is the 8th largest by enrollment, is one of 4 that started in 2024, is one of 8 in phase 1, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 10 studies testing Hemay005 in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Hemay005

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Hemay005 in Psoriasis, or all of them as a file.
02

Study summary

  1. To evaluate the pharmacokinetics of Hemay005 tablets on midazolam and its active metabolite α-hydroxymidazolam after multiple administration;
  2. Evaluate the effect of Hemay005 tablet on QT interval;
  3. To investigate the effect of Hemay 005 tablets on inflammatory factors.
Read the detailed description
  1. To evaluate the pharmacokinetics of Hemay005 tablets on midazolam and its active metabolite α-hydroxymidazolam after multiple administration;
  2. Evaluate the effect of Hemay005 tablet on QT interval;
  3. To investigate the effect of Hemay 005 tablets on inflammatory factors.
  4. The safety of the subjects was evaluated
03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged from 18 to 65 years old (including 18 and 65 years old), the ratio of male to female was 1:1;
  • Body weight: male ≥50.0kg, female ≥45.0kg, [BMI= weight (kg)/height 2 (m2)] between 19.0 kg/m2 and 26.0kg/m2 (including boundary values);
  • 90mmHg≤ systolic blood pressure \<140mmHg, 60mmHg≤ diastolic blood pressure \<90 mmHg, 60 beats/min ≤ pulse ≤100 beats/min, normal body temperature (abnormal vital signs could be retested, normal retest results were considered to meet the inclusion criteria);
  • The results of were normal or abnormal but not , including ≤450 ms in men and QTcF≤470 ms in women, PR interval

    • 200ms and QRS complex duration ≤110 ms;
  • Before the trial, they have understood the nature, significance, possible benefits, possible inconvenience and potential risks of the trial in detail, and voluntarily participate in the clinical trial, can communicate well with the investigators, comply with the requirements of the whole study, and sign the written .

Exclusion criteria

Exclusion Criteria:

  • those who participated in other drug clinical trials within 3 months;
  • patients with abnormal clinical manifestations that need to be excluded, including but not limited to diseases of the nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal system, respiratory system, metabolic system, skeletal system and other systems, especially patients with myasthenia gravis, schizophrenia and severe depression;
  • patients with any disease that increases the risk of bleeding, such as active or previous history of gastrointestinal ulcer, gastrointestinal bleeding or perforation, ulcerative colitis, or intracranial hemorrhage;
  • a history of vomiting, diarrhea, or any physiological condition that could interfere with the test results within 7 days before the test;
  • those with a history of specific allergies (asthma, urticaria, eczema, etc.), or allergic to any drug, food or pollen, or known allergic to Hemay 005, midazolam or other benzodiazepines;
  • those who have lost or donated more than 400mL of blood within 3 months before the trial, or intend to donate blood during the trial;
  • Pregnant or lactating women, or subjects (including male subjects) have plans to have children or to donate sperm or eggs from two weeks before the study to three months after the last dose of the study, and are unwilling or unable to take effective measures;
  • general physical examination and laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, stool routine, blood β-human chorionic gonadotropin/urine pregnancy (female), etc.) within 7 days before the test, chest X-ray within 1 month before the test, and (ECG) within 14 days before the test judged by clinicians to be ;
  • persons with one or more positive results of surface antigen, virus antibody, antigen antibody or syphilis specific antibody;
  • patients with clinically significant major diseases or major surgical procedures within 3 months before the trial;
  • drank more than 14 units of alcohol per week (1 unit = 17.7 mL ethanol, i.e. 1 unit = 357 mL of 5% beer or 43 mL of 40% liquor or 147 mL of 12% wine) in the 3 months before the trial, or could not abstain from alcohol during the trial;
  • who smoked more than 5 cigarettes per day in the 3 months before the trial, or who could not stop using any tobacco products during the trial;
  • consuming excessive amounts of tea, coffee and/or caffeine-rich beverages (> 8 cups, 1 cup =250 mL) per day in the 3 months before the trial;
  • consuming any foods or drinks (such as strong tea, coffee, chocolate, cola, animal organs, grapefruit, dragon fruit, mango, etc.) rich in caffeine/xanthine or other special ingredients (such as strong tea, coffee, chocolate, cola, animal organs, grapefruit, dragon fruit, mango, etc.) from screening to -2 days of admission, or unable to stop eating the above foods or drinks during the trial;
  • use of any drugs (e.g., inducers - barbiturates, carbamazepine, phenytoin, ) that inhibit or induce hepatic drug-metabolizing enzymes within 30 days before the test; Inhibitors (SSRI antidepressants, cimetidine, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines);
  • those who are unable to eat or have dysphagia, have special dietary requirements and/or cannot follow a uniform diet;
  • patients with a history of asthma or seizures;
  • who used any prescription medication, over-the-counter medication, nutrine, herbal medicine product or received a vaccination within 14 days before the trial; Or plan to take non-trial drugs or supplements during the trial; Or use of a drug for less than 5 half-lives before taking the study drug, whichever is longer;
  • Mechanical operators engaged in high-altitude work, motor vehicle driving and other dangerous operations;
  • those who cannot tolerate venipuncture and/or have a history of dizzy with blood or needles;
  • had used any drug in the past year;
  • alcohol breath test results > 0.0mg/100mL or drug abuse screening positive (morphine, methamphetamines, ketamine, dimethylenedioxyamphetamine, tetrahydrocannabinol acid, cocaine);
  • Subjects who were considered by the investigator to have poor adherence or any factor that precluded participation in the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Healthy subject

    Midazolam maleate tablets 15 mg were taken orally in the morning on Day1, and Hemay005 tablets were taken daily on Day3-Day9, twice a day, 60mg once. Midazolam maleate tablets 15 mg+Hemay005 tablets 60mg were taken orally in the morning of Day10

    Drug: Hemay005 · Drug: Midazolam maleate

Interventions

  • One 15mg tablet, four tablets at a time

    Also known as: Hemay005 tablet

  • One 15mg tablet, one tablet at a time

    Also known as: Midazolam maleate tablet

06

What researchers measure

Primary outcomes

  1. Relevant pharmacokinetic parameters,Peak Plasma Concentration(Cmax)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day12

  2. Relevant pharmacokinetic parameters,Area under the plasma concentration versus time curve(AUC0-t)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day12

  3. Relevant pharmacokinetic parameters,Area under the curve from time 0 extrapolated to infinite time (AUC0-inf)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day12

Secondary outcomes

  1. QT interval

    All subjects who receive the drug will be analyzed for QT interval

    Time frame: Day1,Day3-9

  2. Detection of inflammatory factors

    The concentrations of certain cytokines were determined,for example: CRP (C-reactive protein), Haptoglobin (haptoglobin), Fibrinogen (fibrinogen), albumin (albumin), IL-6 (interleukin-6), TNF-α (tumor necrosis factor-α), MCP-1 (monocyte chemoattractant protein-1), MCP-3 (McP-3). Monocyte chemoattractant protein-3 (McT-3), calprotectin, CD11b and CD66b .

    Time frame: Day1,Day9

07

Study locations

1 site
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jan 2025, 1 month.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Sep 24, 2024
StartActual
Dec 12, 2024
Primary completionActual
Jan 20, 2025
CompletionActual
Jan 20, 2025
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06610890
Lead sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Sep 24, 2024
Start date
Dec 12, 2024
Primary completion
Jan 20, 2025
Completion
Jan 20, 2025
Last update
Dec 3, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemay005

Start the discussion